T-cell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment
A Vidaller, L Llorente, F Larrea, JP Mendez… - Clinical immunology and …, 1986 - Elsevier
We studied four patients with tumoral hyperprolactinemia and normal ovarian function
before and after prolactine levels had become normal with treatment with bromocriptine
(BrC), a dopamine agonist that inhibits prolactin release. Their proliferative responses to
concanavalin A, pokeweed mitogen, and, to a lesser extent, phytohemagglutinin, their
spontaneous and concanavalin A-induced suppression, and their production of interleukin 2
were found to be decreased and to correct partially or completely after bromocriptine …
before and after prolactine levels had become normal with treatment with bromocriptine
(BrC), a dopamine agonist that inhibits prolactin release. Their proliferative responses to
concanavalin A, pokeweed mitogen, and, to a lesser extent, phytohemagglutinin, their
spontaneous and concanavalin A-induced suppression, and their production of interleukin 2
were found to be decreased and to correct partially or completely after bromocriptine …